Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question
The CDK4/6 inhibitor showed progression-free survival in patients with breast cancer in an interim analysis, and Lilly plans to begin global regulatory submissions for the drug in the second quarter.
You may also be interested in...
While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.
The latest drug development news and highlights from our US FDA Performance Tracker.
Lilly's first quarter benefited from rising sales for most of its diabetes products, which has become one of the most difficult therapeutic areas to do business in due to competitive and reimbursement pressures.